-
Sinqi Pharmaceutical Gets NMPA Green Light for SQ-22031 Eye Drops to Treat Dry Eye Syndrome and Neurotrophic Keratitis
•
Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its therapeutic biologic, SQ-22031 eye drops. This Category 1 therapeutic biologic is intended for the treatment of dry eye syndrome and neurotrophic keratitis, with…
-
CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment
•
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on track to obtain priority review statuses. These include Shenyang Sinqi Pharmaceutical Co. Ltd.’s atropine for arresting the progression of myopia in children, Zhuhai Jinzhidun Pharmaceutical Technology Co., Ltd.’s trientine for hepatolenticular degeneration that cannot tolerate…
